Detalhe da pesquisa
1.
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Oncologist
; 28(1): 80-83, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36434677
2.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469185
3.
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Invest New Drugs
; 38(5): 1588-1597, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32246224
4.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet
; 389(10072): 917-929, 2017 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126333
5.
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
BMC Cancer
; 18(1): 178, 2018 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433474
6.
Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.
Curr Oncol Rep
; 20(Suppl 1): 18, 2018 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29508085
7.
Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
Eur Radiol
; 27(9): 3733-3743, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28210799
8.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Nature
; 462(7276): 1070-4, 2009 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20033049
9.
Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer.
Eur Respir J
; 42(5): 1357-64, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520312
10.
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Clin Lung Cancer
; 24(6): 483-497, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451931
11.
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
Target Oncol
; 18(6): 927-939, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921939
12.
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
FEBS Lett
; 597(18): 2301-2315, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468447
13.
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
bioRxiv
; 2023 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965202
14.
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Lung Cancer
; 186: 107393, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839252
15.
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Mol Oncol
; 17(11): 2257-2274, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36799689
16.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270698
17.
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.
Transl Lung Cancer Res
; 11(12): 2412-2417, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36636412
18.
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Ther Adv Med Oncol
; 14: 17588359221099399, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35694190
19.
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
J Clin Oncol
; 40(7): 719-728, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073148
20.
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Clin Lung Cancer
; 23(4): 320-332, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466070